Abstract: An improved process for the N-alkylation of tertiary morphinan alkaloid bases to form the corresponding quaternary morphinan alkaloid derivatives.

Abstract: The present invention provides targeted delivery compositions and methods of using the compositions for treating and diagnosing a disease state in a subject.

Abstract: In one characterization, the present invention relates to a radiation-shielding assembly for holding a container having a radioactive material disposed therein. The assembly may, at least in one regard, be referred to as an elution shield and/or a dispensing shield. The assembly includes a body at least partially defining a cavity. There is at least one opening through the body into the cavity. The assembly may include a cap that at least generally hinders escape of radiation from the assembly through the opening. The cap may be releasably attached to the body in one orientation and may establish non-attached engagement with the body in another orientation. The assembly may include an adjustable spacer system for adapting the assembly for use with containers having different heights.

Abstract: The present invention provides processes for the preparation of saturated ketone morphinan compounds by catalytic isomerization. In particular, the invention provides processes for the conversion of a morphinan comprising an allyl alcohol ring moiety into a morphinan comprising a saturated ketone ring moiety by an isomerization reaction catalyzed by an allyl-transition metal catalyst.

Abstract: The present invention generally relates to processes for preparing highly pure morphinan-6-one products. The processes involve reducing the concentration of ?,?-unsaturated ketone compounds present as impurities in morphinan 6 one products or reaction mixtures including morphinan 6 one compounds by treatment with a sulfur-containing compound.

Abstract: Systems and methods are presented for delivering medical fluids to a patient. A data storage device (120) is either separately attached to or incorporated within the structure of a reusable fixture that may be detachably connected to a barrel (111) of a syringe (107). A filling station (110) and an power injector (108) may each include a read-write device (114, 122) that is operable to read the data storage device (120) within its field of view. When the read-write devices (114, 122) are attached to the filing station (110) and the power injector (40), respectively, and when the fixture including the data storage device (120) is attached to the syringe (107), the read-write devices (114, 122) may be operable to store data on and read data from the data storage device (120) associated with the syringe (107). After an injection procedure, the fixture may be detached from the syringe (107) and reused with a new or resterilized syringe (107).

Abstract: The invention relates generally to optical agents for biomedical applications, including phototherapy. Provided are disulfide compounds having an acyclic S—S bond with at least one aromatic and/or heterocyclic aromatic group providing phototherapeutic agents, including Type 1 phototherapeutic agents. Optical agents of the invention enable a versatile phototherapy platform for treatment of a range of pathological conditions, including the treatment of cancers, stensosis and inflammation. The invention further provides preparations and formulations comprising the disulfide optical agents and related methods of making and using disulfide optical agents in an in vivo or ex vivo biomedical procedure.

Abstract: Pharmaceutical product dispensers (e.g., in the shape of a common ink pen) are operable to indicate information regarding a dosing schedule of a pharmaceutical product dispensable from the dispenser. Embodiments of the dispensers may include a plurality of dosing segments, each corresponding to a different dose of the pharmaceutical product. Actuation of an actuator may result in interaction between the actuator and the pharmaceutical product storage area such that a dose of pharmaceutical product contained in the pharmaceutical product storage area is dispensed, along with a corresponding advancement of the plurality of dosing segments. The dispenser may also include one or more locks to prevent unauthorized access to the pharmaceutical product (e.g., by a child or the like). Furthermore, the pharmaceutical product dispenser may include a disabling mechanism to permanently disable actuation of the actuator of the dispenser.

Abstract: A pharmaceutical product supply is disclosed in the form of a container, a pharmaceutical product receiver, pharmaceutical product, an adhesive, and at least one release liner. The pharmaceutical product receiver includes a plurality of receptacles for pharmaceutical product. The container is initially disposed in a first configuration where all of the pharmaceutical product receiver receptacles may be accessible. The container is thereafter disposable in a second configuration where no covering for any of the pharmaceutical product receiver receptacles is accessible through any openable access incorporated by the container. One or more release liners may be moved to expose adhesive for disposing and retaining the container in its second configuration. The noted second configuration of the container facilitates disposal of the pharmaceutical product supply (e.g.

Abstract: A pharmaceutical product supply including primary packaging (e.g., a blister card) having a plurality of receptacles and pharmaceutical product (e.g., one or more pills, capsules, etc.) enclosed within at least one of the receptacles. Heating the pharmaceutical product supply to at least an activation temperature of a heat-activated encapsulation material associated with the supply may encapsulate the pharmaceutical product to reduce the likelihood that the pharmaceutical product can thereafter be administered, and thereby facilitates disposal of the pharmaceutical product. In one embodiment, a tray of a primary packaging is constructed of the heat-activated encapsulation material. In another embodiment, primary packaging may be disposed within a cavity of secondary packaging (e.g., carton), and the heat-activated encapsulation material may be in the form of a layer that is also located within the cavity.

Abstract: Various embodiments of pharmaceutical product containers are disclosed. Each pharmaceutical product container includes a cap, a container body, and a locking mechanism. The locking mechanism is disposable from a locked state to an unlocked state at least when the cap is in a closed position relative to the container body (e.g., to define an enclosed space for pharmaceutical product). Once in the locked state and with the cap being in a closed position, the locking mechanism is unable to return to its unlocked state. Pharmaceutical product enclosed within the container with the locking mechanism being in its locked state may then be disposed of in any appropriate manner (e.g., discarded in the trash).

Abstract: The present invention provides an efficient process for preparing N-alkylated opiates. In particular, processes are provided for using a chloride-containing alkylating agent and a bromide or iodide salt to alkylate the corresponding nor-opiate.

Abstract: The present invention provides processes for the preparation of saturated ketone morphinan compounds from a morphinan comprising an allyl alcohol ring moiety, wherein the final product has a low metal content. In particular, the invention provides processes that utilize isomerization reactions catalyzed by transition metal catalysts and the subsequent removal of the transition metal using metal scavengers.

Abstract: A transdermal patch container (10) that includes a container body (16), a first compartment (24), and a second compartment (28) is disclosed. One or more first transdermal patches (34) may be stored in the first compartment (24). One or more second transdermal patches (36) may be stored in the second compartment (28). The first transdermal patches (34) differ from the second transdermal patches (36) in at least one respect. A number of features may be incorporated to reduce the potential of being able to withdraw second transdermal patches (36) out of the second compartment (28). For instance, second transdermal patches (36) may be required to be directed through a slot (44) to enter a second compartment (28i). A flap (66) may be positioned below such a slot (58) within a second storage compartment (28ii). A plurality of vertically spaced or staggered flaps (96) may be positioned within a second storage compartment (28iv).

Abstract: A container (100) for storing transdermal patches is disclosed. The container (100) includes a child-resistant mechanism (112) to reduce the likelihood of access to the transdermal patches (TP) by children. The child-resistant mechanism (112) may include first and second access components (116, 120) that may be disposed in a non-opposing manner and that may be in any appropriate form (e.g., buttons). Activation or engagement of the first and second access components (116, 120) in a particular manner allows the container (100) to assume an open configuration to access and/or load patches. In one arrangement, the first and second access components (116, 120) may be simultaneously engaged (e.g., depressed) to open the container (100). In another arrangement, the first and second access components (116, 120) may be engaged in series in a particular sequence to open the container (100).

Abstract: Systems and methods for monitoring a container (180) for storing a pharmaceutical product (190) are presented. The container (180) may be monitored (210) such that container movement may be detected (212) and logic may be provided for determining if the movement was authorized. In the event of unauthorized movement, an alarm (140) may be activated (214) to alert a user or stakeholder of the unauthorized movement. The movement of the pharmaceutical product container (180) may be detected by way of a motion sensor (120) such as an accelerometer. The alarm (140) may comprise an auditory or visual alarm as well as a network communication indicative of the activation of an alarm. The alarm (140) may be prevented or canceled (218).

Abstract: Systems and methods for managing use of a pharmaceutical product (112) are provided. The systems and methods utilize an external cover (150) and a container (110), along with a first material (160) and a pharmaceutical product (112) that are each contained within an internal space (116) that exists when the external cover (150) is in a closed position relative to the container (110). Release of the first material (160) may bond the external cover (150) to the container (110), may result in the first material (160) coming into contact with the pharmaceutical product (112), or both.

Abstract: In one characterization, the present invention relates to a radiation-shielding assembly for holding a container having a radioactive material disposed therein. The assembly may, at least in one regard, be referred to as an elution shield and/or a dispensing shield. The assembly includes a body at least partially defining a cavity. There is at least one opening through the body into the cavity. The assembly may include a cap that at least generally hinders escape of radiation from the assembly through the opening. The cap may be releasably attached to the body in one orientation and may establish non-attached engagement with the body in another orientation. The assembly may include an adjustable spacer system for adapting the assembly for use with containers having different heights.

Abstract: In one characterization, the present invention relates to a radiation-shielding assembly for holding a container having a radioactive material disposed therein. The assembly may, at least in one regard, be referred to as an elution shield and/or a dispensing shield. The assembly includes a body at least partially defining a cavity. There is at least one opening through the body into the cavity. The assembly may include a cap that at least generally hinders escape of radiation from the assembly through the opening. The cap may be releasably attached to the body in one orientation and may establish non-attached engagement with the body in another orientation. The assembly may include an adjustable spacer system for adapting the assembly for use with containers having different heights.

Abstract: Containers and methods for disposing unused pharmaceutical product are disclosed. Each container (100, 200, 300) may include a container body (104, 204, 304) with an internal chamber (116, 216, 316) for storing pharmaceutical product, along with a cover (124, 224, 324) for selectively limiting access to the chamber (116, 216, 316). An encapsulation component (128, 228, 328) may be selectively disposable within the chamber (116, 216, 316), and may be operable to encapsulate the pharmaceutical product within the container (100, 200, 300). For instance, the encapsulation component (128, 228, 328) may melt and/or flow into contact with the pharmaceutical product and thereafter solidify to encapsulate the pharmaceutical product. The encapsulation component (128, 228, 328) may melt and thereafter solidify between the cover (124, 224, 324) and shell (104, 204, 304) to limit removal of the cover (124, 224, 324) from the shell (104, 204, 304).